iSOFT Hosts Forum to Discuss Future Role of eClinical Trial Technologies

iSOFTiSOFT recently hosted the eClinical Forum to discuss how existing and emerging healthcare environments impact on clinical trials, and the future role of eClinical trial technologies.

The eClinical Forum was formed in 2000 by Pharmaceutical industry representatives with a vision to create a non-commercial and informal environment in which to network with peers, share ideas and experiences, and to shape the future of the clinical research environment.

The meeting was held at iSOFT's headquarters and was opened by iSOFT chief executive Andrea Fiumicelli who explained that despite the enormous progresses made, much needed to be done to improve the delivery of healthcare, and in particular improve safety through better use of information systems.

The clinical trial process was a key focus of the session. Identifying eligible patients for clinical trials is a constant challenge, and 58 per cent of clinical trials fail to achieve their recruitment targets. Dr Joerg Kraenzlein, director of life science at iSOFT described a system which is being developed to help investigators and pharmaceuticals companies conduct clinical trials more easily. "We want to build a network for physicians to collaborate, foster the use of personalised medicine and the production of clinical trials helping to speed up the process," he explained.

In the iSOFT system under development, patient records are de-identified and medical terms extracted to create the AccelCDB (Clinical Database). The investigator can then use the AccelFind web base application to identify suitable patients for the trial by defining the inclusion and exclusion criteria.

"It just takes 5 to 10 seconds to screen 10,000 medical records, whereas with a manual process a physician has to work for weeks," Dr Kraenzlein said.

The forum agreed that there is an urgent need for an integrated solution for research activities to increase efficiency while maintaining a high level of quality. This will help shorten the clinical trial process and ultimately assist in bringing drugs to market in a more timely way.

Related news articles:

About iSOFT a CSC company
Headquartered in Banbury, UK, iSOFT is one of the world's largest healthcare IT companies serving 13,000 healthcare providers in over 40 countries across five continents. Its software product portfolio is one of the most extensive available, covering every aspect of healthcare delivery and planning. These include interoperable e-health solutions that build on existing systems to maximize current investments.

iSOFT's business is driven by the collective talent, experience and commitment of over 3,000 specialists in 19 countries. Through a global network of subsidiaries and extensive partner network, iSOFT also has substantial experience of national healthcare sectors and expert knowledge of local market needs.

iSOFT is a CSC Company.

Most Popular Now

Stanford Medicine Study Suggests Physici…

Artificial intelligence-powered chatbots are getting pretty good at diagnosing some diseases, even when they are complex. But how do chatbots do when guiding treatment and care after the diagnosis? For...

OmicsFootPrint: Mayo Clinic's AI To…

Mayo Clinic researchers have pioneered an artificial intelligence (AI) tool, called OmicsFootPrint, that helps convert vast amounts of complex biological data into two-dimensional circular images. The details of the tool...

Adults don't Trust Health Care to U…

A study finds that 65.8% of adults surveyed had low trust in their health care system to use artificial intelligence responsibly and 57.7% had low trust in their health care...

Testing AI with AI: Ensuring Effective A…

Using a pioneering artificial intelligence platform, Flinders University researchers have assessed whether a cardiac AI tool recently trialled in South Australian hospitals actually has the potential to assist doctors and...

AI Unlocks Genetic Clues to Personalize …

A groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence cancer treatment outcomes - insights that could help doctors tailor...

The 10 Year Health Plan: What do We Need…

Opinion Article by Piyush Mahapatra, Consultant Orthopaedic Surgeon and Chief Innovation Officer at Open Medical. There is a new ten-year plan for the NHS. It will "focus efforts on preventing, as...

Deep Learning to Increase Accessibility…

Coronary artery disease is the leading cause of death globally. One of the most common tools used to diagnose and monitor heart disease, myocardial perfusion imaging (MPI) by single photon...

People's Trust in AI Systems to Mak…

Psychologists warn that AI's perceived lack of human experience and genuine understanding may limit its acceptance to make higher-stakes moral decisions. Artificial moral advisors (AMAs) are systems based on artificial...

Relationship Between Sleep and Nutrition…

Diet and sleep, which are essential for human survival, are interrelated. However, recently, various services and mobile applications have been introduced for the self-management of health, allowing users to record...

DMEA 2025 - Innovations, Insights and Ne…

8 - 10 April 2025, Berlin, Germany. Less than 50 days to go before DMEA 2025 opens its doors: Europe's leading event for digital health will once again bring together experts...

New AI Tool Mimics Radiologist Gaze to R…

Artificial intelligence (AI) can scan a chest X-ray and diagnose if an abnormality is fluid in the lungs, an enlarged heart or cancer. But being right is not enough, said...

AI Model can Read ECGs to Identify Femal…

A new AI model can flag female patients who are at higher risk of heart disease based on an electrocardiogram (ECG). The researchers say the algorithm, designed specifically for female patients...